


The burden of antimicrobial resistance (AMR) in Uruguay

Executive summary

- Antimicrobial Resistance (AMR) is a major global health threat, over **700 lives** have been lost each year since 1990 in Uruguay due to AMR.
- In 2021, there were an estimated **683 UI (607-759)** deaths attributable to AMR and **2,830 UI (2,530-3,120)** deaths associated with AMR in this location.
- The largest number of deaths associated with AMR in 2021 occurred among those aged **70+** in the country.
- Among the most deadly pathogen-drug combinations in 2021 were *Staphylococcus aureus* resistant to methicillin, *Pseudomonas aeruginosa* resistant to carbapenems and *Klebsiella pneumoniae* resistant to carbapenems.

Figure 1 Number of deaths by underlying cause, and those associated with AMR in 2021




- In 2021, the number of deaths associated with AMR (orange bar in *figure 2*) were high compared to the most relevant underlying causes of death (depicted in blue) in the country. AMR associated deaths occur within multiple Global Burden of Disease (GBD) causes of death and AMR is not an underlying cause of death by itself.
- At the [2024 United Nations General Assembly high level meeting on antimicrobial resistance](#), country members agreed to aim for a **10% reduction** compared to 2019 baseline (**from 4.95 to 4.45 million**) in the global number of deaths associated with AMR by 2030. But [our forecast](#) indicates that in absence of concerted action, deaths associated with AMR could reach **5.5 million** (UI 4.8 - 6.2) if current trends continue. For Uruguay, a 10% reduction means to decrease the number of deaths associated with AMR to **2,670**, but currently the trend for this country could reach up to **3,010 UI [2,440-3,570]** AMR-associated deaths in 2030.

AMR in Uruguay

Key takeaways

- Antimicrobial Resistance (AMR) is a major global health threat, over *a million lives* have been lost each year since 1990.
- Globally, 4.71 (95% Uncertainty Interval (UI) 4.2-5.2) million deaths were associated with bacterial drug-resistant infections in 2021.
- And 1.14 (UI 1 - 1.3) million deaths were attributable to bacterial drug-resistant infection in the same year.
- *39 (UI 33 - 46) million deaths* directly attributable to bacterial AMR are projected to occur between 2025-2050 unless concerted action is taken. This equates to three deaths every minute.

Figure 2 Comparing 30 years of infection related deaths, and those associated with and attributable to AMR in Uruguay between 1990 and 2019.



- To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#)
- In **Uruguay** in 2021, there were an estimated **683 UI (607-759)** deaths attributable to AMR and **2,830 UI (2,530-3,120)** deaths associated with AMR. Here “*attributable deaths*” are considered to be those that would have been prevented had the drug-resistant bacteria causing the infections not been drug-resistant. “*Associated deaths*” are considered to be those that would not have occurred had the infections been prevented entirely.
- Across 204 countries, **Uruguay has the 82nd lowest** age-standardized mortality rate associated with AMR in 2021.
- *Table 1* shows the bacteria which caused most deaths in 2021 (↑ indicates an increasing estimated annual rate between 1990-2021, ↓ indicates a decreasing annual trend), and *table 2* shows the pathogen-drug combinations which caused most deaths in 2021.

Table 1. Bacteria which cause most deaths in 2021 (Number of deaths in parenthesis)

Burden rank	Overall susceptible and resistant			Associated			Attributable		
	Staphylococcus aureus 1,000 UI (917-1,090)	↑		Escherichia coli 612 UI (464-760)	↑		Staphylococcus aureus 163 UI (103-224)	↑	
	Escherichia coli 825 UI (749-902)	↑		Staphylococcus aureus 560 UI (386-733)	↑		Klebsiella pneumoniae 113 UI (96-131)	↑	
	Pseudomonas aeruginosa 516 UI (474-557)	↑		Klebsiella pneumoniae 389 UI (338-440)	↑		Escherichia coli 108 UI (82-133)	↑	
	Klebsiella pneumoniae 507 UI (463-550)	↑		Pseudomonas aeruginosa 370 UI (331-408)	↑		Pseudomonas aeruginosa 95 UI (77-112)	↑	
	Streptococcus pneumoniae 404 UI (369-439)	↓		Streptococcus pneumoniae 195 UI (155-235)	↓		Acinetobacter baumannii 67 UI (59-75)	↓	
	Acinetobacter baumannii 188 UI (173-202)	↓		Acinetobacter baumannii 174 UI (158-189)	↓		Streptococcus pneumoniae 29 UI (22-36)	↓	
	Group A Streptococcus 179 UI (161-196)	↑		Proteus spp. 106 UI (78-133)	↑		Enterococcus faecium 29 UI (24-33)	↑	
	Proteus spp. 170 UI (154-186)	↑		Enterococcus faecium 100 UI (90-109)	↑		Enterobacter spp. 24 UI (20-28)	↓	
	Enterococcus faecalis 154 UI (141-167)	↑		Enterobacter spp. 94 UI (80-108)	↓		Proteus spp. 16 UI (10-21)	↑	
	Enterobacter spp. 134 UI (122-145)	↑		Enterococcus faecalis 66 UI (57-75)	↑		Serratia spp. 13 UI (10-16)	↓	

Annualized rate of change (1990-2021)

<-3% -1.5% to 0% 1.5% to 3% >5.0%
 -3% to -1.5% 0% to 1.5% 3% to 5%

Table 2. Combinations which cause most deaths in 2021 (Number of deaths in parenthesis)


Burden Rank	Associated			Attributable		
	Escherichia coli Aminopenicillin	582 UI (368-795)	↑	Staphylococcus aureus Methicillin	131 UI (72-189)	↑
	Staphylococcus aureus Methicillin	494 UI (274-714)	↑	Pseudomonas aeruginosa Carbapenems	48 UI (30-67)	↑
	Klebsiella pneumoniae Aminoglycosides	371 UI (322-419)	↑	Klebsiella pneumoniae Carbapenems	40 UI (30-50)	↑
	Escherichia coli TMP-SMX	326 UI (234-418)	↑	Klebsiella pneumoniae Aminoglycosides	33 UI (26-40)	↑
	Staphylococcus aureus Macrolides	300 UI (228-371)	↑	Escherichia coli Aminopenicillin	30 UI (11-49)	↑
	Klebsiella pneumoniae Fluoroquinolones	297 UI (239-354)	↑	Acinetobacter baumannii Carbapenems	27 UI (19-35)	↑
	Pseudomonas aeruginosa Carbapenems	276 UI (231-321)	↑	Pseudomonas aeruginosa Fluoroquinolones	26 UI (18-34)	↑
	Pseudomonas aeruginosa Fluoroquinolones	274 UI (232-316)	↑	Klebsiella pneumoniae Fluoroquinolones	24 UI (17-32)	↑
	Escherichia coli Beta-Lactam/Lactamase Inhib.	262 UI (210-313)	↑	Acinetobacter baumannii Fluoroquinolones	23 UI (19-27)	↓
	Klebsiella pneumoniae Beta-Lactam/Lactamase Inhib.	256 UI (182-331)	↑	Enterococcus faecium Vancomycin	21 UI (17-25)	↑

Annualized rate of change (1990-2021)

<-3% -1.5% to 0% 1.5% to 3% >5.0%
 -3% to -1.5% 0% to 1.5% 3% to 5%

- Independently of antimicrobial resistance, the infectious syndromes accounting for the most deaths in 2021 were as follows (estimated thousands of deaths in parenthesis) lower respiratory infection (excl. COVID) (2,400 UI (2,160-2,640)), bloodstream infections (1,950 UI (1,790-2,110)), urinary tract infections and pyelonephritis (917 UI (809-1,030)), peritoneal and intra-abdominal infections (708 UI (641-775)) and infections of the skin and subcutaneous systems (391 UI (347-435)).

Figure 3. Number of deaths associated with AMR by age group between 1990-2020 and 2050 projection



- In Uruguay, people aged 70+ saw the largest number of deaths associated with AMR both in 1990 and 2021, which indicates that 70+ continues to be particularly vulnerable to infections which are resistant to antibiotics. In 2021, the number of deaths associated with AMR among the 70+ was 2,100 UI (1,840-2,350), whereas the mortality rate per 100,000 was 559 UI (491-627).

Data sources for Uruguay

In total, 520 million individual records or isolates covering 19,513 study-location-years were used as input data to our estimation process. The subset of input data for this country is shown below.

Table 3. Data inputs for Uruguay by source type

Source type	Years	Sample size	Sample size units
Literature studies	1990-2021	563	Cases/isolates/susceptibility tests
Single drug resistance profile data	1990-2021	14,751	Antibiotic susceptibility test

More information

About GRAM:

The purpose of the Global Research on AntiMicrobial resistance (GRAM) project is to **generate accurate and timely estimates of the magnitude and trends in antimicrobial resistance (AMR) burden** across the world, which can be used to inform treatment guidelines and agendas for decision-making and research, detect emerging problems and monitor trends to inform global strategies, as well as facilitate the assessment of interventions over time.

GRAM is the flagship project of the University of Oxford–IHME Strategic Partnership. GRAM was launched with support from the United Kingdom Department of Health and Social Care's Fleming Fund, and the Wellcome Trust.

All resources:

For all resources on AMR analysis at IHME, visit <https://www.healthdata.org/antimicrobial-resistance>.

To look at these and more visualization interactively visit [Measuring Infectious Causes and Resistance Outcomes for Burden Estimation \(MICROBE\)](#).

Data sources:

To download the list of data input sources by country, and AMR results by region, visit the [Global Health Data Exchange \(GHDx\)](#).

Contact us:

- For inquiries about the analysis and questions from government officials, health departments, or research institutions: engage@healthdata.org
- For media-related inquiries: media@healthdata.org
- **Bluesky:** @ihmeuw.bsky.social
- **Twitter:** @IHME_UW
- **Facebook:** <https://www.facebook.com/IHMEUW>
- **LinkedIn:** <https://www.linkedin.com/company/institute-for-health-metrics-and-evaluation>